Roche’s Kadcyla (trastuzumab emtansine) Receives FDA’s Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US

 Roche’s Kadcyla (trastuzumab emtansine) Receives FDA’s Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US

Roche’s Kadcyla (trastuzumab emtansine) Receives FDA’s Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US

Shots:

  • The approval is based on P-III KATHERINE study results assessing Kadcyla versus Herceptin in patients with HER2+ early breast cancer (eBC) with the residual invasive disease after neoadjuvant treatment included Herceptin and taxane-based CT
  • The P-III KATHERINE study results: reduction in risk of breast cancer recurrence (50%); @3yrs. iDFS (88.3% vs 77.0%); absolute improvement (11.3%); worse prognosis in patients with residual disease after neoadjuvant treatment
  • Kadcyla (trastuzumab emtansine) is an ADC, a combination of trastuzumab and DM1, delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen

Click here to read full press release/ article | Ref: Roche | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post